科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一,在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业,通过齐心协力确保高品质治疗与成功康复。

行此手术的医生

编辑搜索过滤条件
close

缩小搜索范围

重置所有过滤器

显示$起始范围 - $结束范围/源自可用$可用医生

姓氏首字母: J

  1. Avni Y. Joshi, M.D., M.S.

    Avni Y. Joshi, M.D., M.S.

    1. Allergist-Immunologist
    2. Pediatric Infectious Disease Specialist
    3. Pediatric Allergist-Immunologist
    1. Rochester, MN
    擅长领域:

    Bone marrow transplant, Immune deficiencies, Primary immunodeficiency

研究

妙佑医疗国际的科学家正在积极研究改善骨髓移植预后的相关方法。研究领域包括:

  • 扩展单倍体相合骨髓移植的应用范围
  • 寻找使用骨髓移植的新方法,包括小儿血红蛋白病和遗传性代谢病
  • 改善骨髓移植幸存者的生活质量
  • 预防和应对移植物抗宿主病(GVHD)
  • 了解慢性 GVHD

了解更多关于骨髓移植项目的相关研究。

癌症研究系与妙佑医疗国际综合癌症中心合作开展。癌症中心获得美国国家癌症研究所的资助,是指定的综合癌症中心 — 这是对其致力于癌症预防、诊断和治疗的卓越科学成就和多学科资源的认可。

文献

请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗国际医生在骨髓移植领域的文献著述列表

Research Profiles

March 28, 2024
  1. AskMayoExpert. Hematopoietic stem cell transplant. Mayo Clinic; 2020.
  2. Hoffman R, et al. Overview and choice of donor of hematopoietic stem cell transplantation. In: Hematology: Basic Principles and Practice. 7th ed. Elsevier; 2018. https://www.clinicalkey.com. Accessed Jan. 28, 2022.
  3. Blood-forming stem cell transplants. National Cancer Institute. http://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant/stem-cell-fact-sheet. Accessed Jan. 28, 2022.
  4. Majhail NS. How to perform hematopoietic stem cell transplantation. JACC CardioOncology. 2021; doi:10.1016/j.jaccao.2021.09.012.
  5. Diseases treatable by transplants. National Marrow Donor Program. https://bethematch.org/transplant-basics/how-transplants-work/diseases-treatable-by-transplants/. Accessed Jan. 27, 2022.
  6. AskMayoExpert. Cutaneous graft-versus-host disease (adult). Mayo Clinic; 2021.
  7. Blood and marrow stem cell transplantation. Leukemia & Lymphoma Society. https://www.lls.org/resource-center/download-or-order-free-publications. Accessed Jan. 28, 2022.
  8. Chao NJ. Survival, quality-of-life and late complications after hematopoietic cell transplantation in adults. https://www.uptodate.com/contents/search. Accessed Feb. 10, 2022.
  9. Blood and bone marrow transplant. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health-topics/blood-and-bone-marrow-transplant. Accessed Jan. 28, 2022.
  10. D'Souza A, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biology of Blood and Marrow Transplantation. 2020; doi:10.1016/j.bbmt.2020.04.013.
  11. Hematopoietic stem cell transplantation. Merck Manual Professional Version. https://www.merckmanuals.com/professional/immunology-allergic-disorders/transplantation/hematopoietic-stem-cell-transplantation#. Accessed Feb. 10, 2022.
  12. Blood and marrow transplant (BMT): An introduction to allogeneic BMT. Leukemia & Lymphoma Society. https://www.lls.org/resource-center/download-or-order-free-publications. Accessed Jan. 28, 2022.
  13. Participating clinical centers. Primary Immune Deficiency Treatment Consortium. https://www.rarediseasesnetwork.org/cms/pidtc/Learn-More/Participating-Clinical-Centers. Accessed Feb. 18, 2022.
  14. Full membership institutions. Pediatric Transplantation and Cellular Therapy Consortium. http://www.pbmtc.org/about/members/full. Accessed Feb. 18, 2022.
  15. Participating institutions. ECOG-ACRIN Cancer Research Group. https://ecog-acrin.org/participating-institutions. Accessed Feb. 18, 2022.
  16. Mills SD, et al. Bone-marrow transplant in an identical twin. JAMA. 1964; doi:10.1001/jama.1964.03060380005001.
  17. Rashidi A, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances. 2019; doi:10.1182/bloodadvances.2019000050.
  18. Ahmed S, et al. Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 2019; doi:10.1016/j.bbmt.2019.05.025.
  19. Jain T, et al. Choosing a reduced-intensity conditioning regimen for allogeneic stem cell transplantation, fludarabine/busulfan versus fludarabine melphalan: A systematic review and meta-analysis. Biology of Blood and Marrow Transplantation. 2019; doi:10.1016/j.bbmt.2018.11.016.
  20. Chen YB, et al. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Advances. 2019; doi:10.1182/bloodadvances.2018027599.
  21. Ballen KK, et al. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: Comparison among alternative graft sources. Biology of Blood and Marrow Transplantation. 2014; doi:10.1016/j.bbmt.2014.07.021.
  22. Sweeney SK, et al. Tracking embryonic hematopoietic stem cells to the bone marrow: Nanoparticle options to evaluate transplantation efficiency. Stem Cell Research & Therapy. 2018; doi:10.1186/s13287-018-0944-8.
  23. Kumar A, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis: An updated systematic review and meta-analysis. Bone Marrow Transplantation. 2019; doi:10.1038/s41409-018-0393-0.
  24. Graff TM, et al. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant. 2015; doi:10.1038/bmt.2015.46.
  25. Braswell Pickering EA. Allscripts EPSi. Mayo Clinic. March 1, 2022.
  26. Search for a FACT accredited organization. Foundation for the Accreditation of Cellular Therapy (FACT). http://accredited.factwebsite.org/. Accessed Feb. 18, 2022.
  27. Transplant center search results. Be The Match. https://bethematch.org/tcdirectory/search/advanced/#mayo/-/-/false/-. Accessed Feb. 18, 2022.
  28. Participating transplant centers. Center for International Blood and Marrow Transplant Research. https://www.cibmtr.org/About/WhoWeAre/Centers/Pages/index.aspx?country=us&state=Minnesota. Accessed Feb. 18, 2022.
  29. Locations. Children's Oncology Group. https://childrensoncologygroup.org/index.php/locations/. Accessed Feb. 18, 2022.